4D Molecular Therapeutics
FDMT
145 hedge funds and large institutions have $262M invested in 4D Molecular Therapeutics in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 27 closing their positions.
132% more call options, than puts
Call options by funds: $858K | Put options by funds: $370K
19% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 27
4% more funds holding
Funds holding: 140 → 145 (+5)
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
10.73% less ownership
Funds ownership: 112.06% → 101.33% (-11%)
58% less capital invested
Capital invested by funds: $630M → $262M (-$369M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$10.5M |
| 2 |
Goldman Sachs
New York
|
+$5.37M |
| 3 |
JP Morgan Chase
New York
|
+$3.96M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.75M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$37M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$27.4M |
| 3 |
VA
VR Adviser
New York
|
-$11.4M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$9.06M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.88M |
FDMT Hedge Fund Activity: Q4 2024 in Review
145 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q4 2024, worth a combined $262M — down 58% from $630M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new FDMT positions and 27 closed out — a net gain of 5 holders — while 50 added to existing stakes and 46 trimmed.
The largest buyer was Millennium Management, adding an estimated $10.5M. The largest seller was BVF Inc, cutting an estimated $37M.
- 145 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q4 2024, up from 140 in Q3 2024.
- Funds reported $262M of 4D Molecular Therapeutics stock for Q4 2024, down 58% quarter-over-quarter.
- 32 funds opened new 4D Molecular Therapeutics positions in Q4 2024 and 27 closed out, a net change of +5 holders.
- The largest 4D Molecular Therapeutics buyer in Q4 2024 was Millennium Management, an estimated $10.5M added.
- The largest 4D Molecular Therapeutics seller in Q4 2024 was BVF Inc, an estimated $37M sold.
Based on aggregated 13F filings for Q4 2024.